In this issue
mAbs
Volume 2, Issue 5September/October 2010
View current issue
About the cover
The cover illustration shows the Upstream (upper panel) and Downstream Manufacturing Suites (lower panel) at Genentech Inc., a member of the Roche Group....Continue reading
Issue Highlights
Focus on bioprocessing
About the Journal
mAbs accepted for inclusion for Medline 11.6.09
In January of 2009 mAbs, the first international peer-reviewed journal of its kind to focus exclusively on monoclonal antibodies, was launched. We believe that this is an excellent time to start the journal because of the increasing focus on mAbs as therapeutics. There has been a rapid increase in mAb R&D by academia, government and industry located world wide. Novel mAb therapeutics are entering clinical study by commercial sponsors at a record pace (Figure 1) that is predicted to continue well into the future. MAbs have proven successful in the clinic (Table 1). In addition, a global market has emerged for the products - several novel mAbs not yet available in the US or EU are now approved in China.
HINARI
Landes Bioscience gladly participates in the World Health Organizations' Access to Research Initiative (HINARI) to provide free online access to all papers published in mAbs to scientists in developing countries worldwide.
Editor-in-Chief
Janice M. Reichert, Ph.D.
Email the Managing Editor.
Online ISSN: 1942-0870 DOI: 10.4161/mabs
mAbs is indexed in:
Most Popular Downloads
Leslie A. Khawli, Sirj Goswami, Ryan Hutchinson, et al.
John McCafferty
Janice M. Reichert
Diane E. Milenic, Karen J. Wong, Kwamena E. Baidoo, et al.
Thomas Schirrmann, Christian Menzel, Michael Hust, et al.
Meetings of interest
BioPharm AmericaTM 2010
September 15–17, 2010
Boston, MA USA
Targeted Cancer Therapies World Congress Europe
September 21–23, 2010
Zurich, Switzerland
Links of Interest
